About Us

Almedtrac, Inc. is a University of Pittsburgh (Pitt) spin-off that started full product development in February of 2008. Rick Engberg, founder and inventor, provided IT support to over 100 clinical trials during his 16 years with Pitt. During that time, he created Study 360™ software to solve an unaddressed problem that he observed in all clinical trials: Protocol Management.

Existing methods of managing clinical trial protocols lack a rigorous and systematic approach. As a result, clinical trials are wasteful, expensive, and inaccurate. Current practice is to employ some combination of paper systems, general-purpose databases, spreadsheet systems (e.g. Access®, Excel®), and custom built software. None of these adequately address the challenge of accurately managing day-to-day trial operations. It has been reported that trial management accounts for up to 60% of overall trial costs (DCRI). Current methods:

  • Create cost and time overruns
  • Increase the risk for trial errors and protocol violations
  • Ultimately, increase the risk for regulatory and legal action

Study 360 solves these problems by automating the workflow and creating a data trail that then becomes the foundation of the clinical trial management process. The software provides real-time tracking, multi-site coordination, and the opportunity for interim analysis.

Management Team

Michael Malley – Founder & CEO
Mr. Malley is a highly successful sales representative for medical supply OEMs who has founded and led several successful companies in the medical industry.

Rick Engberg – Founder & CTO
Mr. Engberg worked at University of Pittsburgh for over 16 years supporting NIH funded clinical trials and is an expert in the field of academic clinical trials and NIH operations.

Diane Hill – VP, Sales & Marketing
Ms. Hill ran a product repositioning campaign at Cordis, a division of Johnson & Johnson, that increased sales from $12 thousand to $100M in 18 months.

Board of Directors

Paul Kornblith, MD – Chairman & Advisor, Founder & Chairman Emeritus, Precision Therapeutics Inc (PTI)
Dr. Kornblith was the head of neurosurgery at the NIH for 8 years and founder of PTI, a company that has raised $127M in capital and with current revenues of $40M per year.

John W. Manzetti – President  & CEO, Pittsburgh Life Sciences Greenhouse
Mr. Manzetti was previously CEO of NOMOS Corporation, a leading radiation therapy company, and EVP and CFO of Carnegie Group, a leading developer of custom knowledge-based solutions for industry, where he raised over $150M in capital for those organizations.

Charlie O’Hanlon – President & CEO, Celsense Inc
Mr. O’Hanlon was previously a Managing Director of Cornerstone Capital Advisors, Ltd., a boutique financial advisory firm based in Pittsburgh.  Prior to that Mr. O’Hanlon enjoyed a 30 year career in banking.

Mike Malley – Founder & CEO

Rick Engberg – Founder & CTO